{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:59:41Z","timestamp":1790283581146,"version":"4.1.0"},"reference-count":21,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.3892\/ijo.2013.1986","type":"journal-article","created":{"date-parts":[[2013,6,13]],"date-time":"2013-06-13T09:24:18Z","timestamp":1371115458000},"page":"670-676","source":"Crossref","is-referenced-by-count":10,"title":["Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine"],"prefix":"10.3892","volume":"43","author":[{"given":"KANDASAMY","family":"HARIHARAN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PETER","family":"CHU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TRACEY","family":"MURPHY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DANA","family":"CLANTON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LISA","family":"BERQUIST","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ARTURO","family":"MOLINA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"STEFFAN N.","family":"HO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARIO I.","family":"VEGA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BENJAMIN","family":"BONAVIDA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2013,6,13]]},"reference":[{"key":"key20180107183204_b1-ijo-43-02-0670","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJM199304083281409","article-title":"Treatment of non-Hodgkin\u2019s lymphoma","volume":"328","author":"Armitage","year":"1993","journal-title":"N Engl J Med"},{"key":"key20180107183204_b2-ijo-43-02-0670","first-page":"280","article-title":"New therapeutic targets and drugs in non-Hodgkin\u2019s lymphoma","volume":"18","author":"Sawas","year":"2011","journal-title":"Curr Opin Hematol"},{"key":"key20180107183204_b3-ijo-43-02-0670","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1002\/cncr.26708","article-title":"Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation","volume":"118","author":"Ferrario","year":"2012","journal-title":"Cancer"},{"key":"key20180107183204_b4-ijo-43-02-0670","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1200\/JCO.2010.32.7577","article-title":"Transformation of indolent B-cell lymphomas","volume":"29","author":"Montoto","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20180107183204_b5-ijo-43-02-0670","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev.med.59.060906.220345","article-title":"A decade of rituximab: improving survival outcomes in non-Hodgkin\u2019s lymphoma","volume":"59","author":"Molina","year":"2008","journal-title":"Annu Rev Med"},{"key":"key20180107183204_b6-ijo-43-02-0670","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/85251","article-title":"The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function","volume":"2","author":"Coyle","year":"2001","journal-title":"Nat Immunol"},{"key":"key20180107183204_b7-ijo-43-02-0670","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4049\/jimmunol.154.1.97","article-title":"CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL","volume":"154","author":"Lanier","year":"1995","journal-title":"J Immunol"},{"key":"key20180107183204_b8-ijo-43-02-0670","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"key20180107183204_b9-ijo-43-02-0670","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1182\/blood.V90.11.4297","article-title":"In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation","volume":"90","author":"Dorfman","year":"1997","journal-title":"Blood"},{"key":"key20180107183204_b10-ijo-43-02-0670","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1182\/blood.V83.3.793.793","article-title":"In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin\u2019s disease","volume":"83","author":"Munro","year":"1994","journal-title":"Blood"},{"key":"key20180107183204_b11-ijo-43-02-0670","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1002\/eji.1830251106","article-title":"Localization in situ of the co-stimulatory molecules B7.1, B7.2, CD40 and their ligands in normal human lymphoid tissue","volume":"25","author":"Vyth-Dreese","year":"1995","journal-title":"Eur J Immunol"},{"key":"key20180107183204_b12-ijo-43-02-0670","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1182\/blood.V82.9.2845.2845","article-title":"The B7\/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin\u2019s disease and contributes to the stimulating capacity of Hodgkin\u2019s disease-derived cell lines","volume":"82","author":"Delabie","year":"1993","journal-title":"Blood"},{"key":"key20180107183204_b13-ijo-43-02-0670","doi-asserted-by":"crossref","first-page":"7766","DOI":"10.1074\/jbc.M105902200","article-title":"Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma","volume":"277","author":"Suvas","year":"2002","journal-title":"J Biol Chem"},{"key":"key20180107183204_b14-ijo-43-02-0670","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1200\/JCO.2005.09.018","article-title":"Phase I\/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma","volume":"23","author":"Czuczman","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180107183204_b15-ijo-43-02-0670","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/annonc\/mdm114","article-title":"A phase I\/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma","volume":"18","author":"Leonard","year":"2007","journal-title":"Ann Oncol"},{"key":"key20180107183204_b16-ijo-43-02-0670","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1093\/annonc\/mdr620","article-title":"Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness","volume":"23","author":"Czuczman","year":"2012","journal-title":"Ann Oncol"},{"key":"key20180107183204_b17-ijo-43-02-0670","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1158\/1535-7163.MCT-11-0635","article-title":"Galiximab signals B-NHL cells and inhibits the activities of NF-kappaB-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmuno-therapeutic drugs","volume":"11","author":"Martinez-Paniagua","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"key20180107183204_b18-ijo-43-02-0670","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3816\/CLM.2003.n.008","article-title":"Initial trials of anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma","volume":"3","author":"Younes","year":"2003","journal-title":"Clin Lymphoma"},{"key":"key20180107183204_b19-ijo-43-02-0670","doi-asserted-by":"crossref","first-page":"8114","DOI":"10.1038\/sj.onc.1208954","article-title":"Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis","volume":"24","author":"Vega","year":"2005","journal-title":"Oncogene"},{"key":"key20180107183204_b20-ijo-43-02-0670","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/sj.onc.1208349","article-title":"Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin\u2019s lymphoma: implications in chemosensitization and therapeutic intervention","volume":"24","author":"Jazirehi","year":"2005","journal-title":"Oncogene"},{"key":"key20180107183204_b21-ijo-43-02-0670","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3109\/10428194.2010.531408","article-title":"A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells","volume":"52","author":"Vega","year":"2011","journal-title":"Leuk Lymphoma"}],"container-title":["International Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijo.2013.1986\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T10:39:18Z","timestamp":1688294358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijo.2013.1986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,13]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,6,13]]},"published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.3892\/ijo.2013.1986"],"URL":"https:\/\/doi.org\/10.3892\/ijo.2013.1986","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,13]]}}}